Aspira Women's Health (AWH)
(Delayed Data from NSDQ)
$1.50 USD
+0.09 (6.38%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.50 USD
+0.09 (6.38%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $1.50 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth C Momentum D VGM
Zacks News
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspira (AWH) delivered earnings and revenue surprises of -8.33% and 2.52%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Masimo (MASI) Beats Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Masimo (MASI) delivered earnings and revenue surprises of 31.58% and 0.93%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Is Aspira Women's Health (AWH) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how Aspira (AWH) and Compugen (CGEN) have performed compared to their sector so far this year.
All You Need to Know About Aspira (AWH) Rating Upgrade to Buy
by Zacks Equity Research
Aspira (AWH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ReWalk Robotics (RWLK) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ReWalk (RWLK) delivered earnings and revenue surprises of 28.57% and 0.15%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Shattuck Labs, Inc. (STTK) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Shattuck Labs, Inc. (STTK) delivered earnings and revenue surprises of 3.85% and 44.44%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AngioDynamics (ANGO) Lags Q4 Earnings Estimates
by Zacks Equity Research
AngioDynamics (ANGO) delivered earnings and revenue surprises of -33.33% and 0.37%, respectively, for the quarter ended May 2023. Do the numbers hold clues to what lies ahead for the stock?
Aspira (AWH) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Aspira (AWH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aspira (AWH) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aspira (AWH) delivered earnings and revenue surprises of -1,360% and 0.70%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
New Strong Buy Stocks for May 11th
by Zacks Equity Research
AMEH, PYCR, AWH, SAND and MCD have been added to the Zacks Rank #1 (Strong Buy) List on May 11, 2023.
Are Medical Stocks Lagging Cardinal Health (CAH) This Year?
by Zacks Equity Research
Here is how Cardinal Health (CAH) and Aspira (AWH) have performed compared to their sector so far this year.
What Makes Aspira (AWH) a New Buy Stock
by Zacks Equity Research
Aspira (AWH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Aspira (AWH) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aspira (AWH) delivered earnings and revenue surprises of 33.33% and 10.29%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Has Aspira Women's Health (AWH) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Here is how Aspira (AWH) and Biomea Fusion, Inc. (BMEA) have performed compared to their sector so far this year.
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Sight Sciences, Inc. (SGHT) delivered earnings and revenue surprises of 16.67% and 0.80%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Neuronetics (STIM) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neuronetics (STIM) delivered earnings and revenue surprises of 30.23% and 9.76%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Asensus Surgical (ASXC) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 0% and 1.44%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Is ASLAN Pharmaceuticals (ASLN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Here is how ASLAN Pharmaceuticals Ltd. (ASLN) and Aspira (AWH) have performed compared to their sector so far this year.
Are Medical Stocks Lagging Editas Medicine (EDIT) This Year?
by Zacks Equity Research
Here is how Editas Medicine (EDIT) and Aspira (AWH) have performed compared to their sector so far this year.
Alphatec (ATEC) Soars 8.4%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Alphatec (ATEC) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
KORU Medical Systems Inc. (KRMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
KORU Medical Systems Inc. (KRMD) delivered earnings and revenue surprises of 40% and 11.66%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inari Medical, Inc. (NARI) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Inari Medical, Inc. (NARI) delivered earnings and revenue surprises of 20.83% and 6.13%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Aspira (AWH) Looks Ripe for Bottom Fishing
by Zacks Equity Research
Aspira (AWH) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Down 38.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Aspira (AWH)
by Zacks Equity Research
The heavy selling pressure might have exhausted for Aspira (AWH) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Intuitive (ISRG) New Lung Biopsy Imaging Technology Gets FDA Nod
by Zacks Equity Research
The FDA clears the integration of mobile cone-beam CT imaging technology with Intuitive's (ISRG) Ion Endoluminal System, enhancing a physician's ability to provide minimally invasive lung biopsy.